Drug Trial Radar · NCT04058587
A Phase I Trial of Simmitinib in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Jun 8, 2020
Primary completion
Jan 31, 2023
Study completion Mar 31, 2023
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
- First posted
- Aug 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, multi-center, phase I study of oral Simmitinib in subjects with advanced solid tumors including gastric cancer.
Conditions
- Advanced Solid Tumor
Interventions
SimmitinibDrug
The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration. The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage. The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limited toxicity (DLT)Time frame: 1 year
- Maximum tolerated dose (MTD)Time frame: 1 year
- Recommended Phase II Dose (RP2D)Time frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.